ATE369848T1 - Verwendung von d-serine oder d-alanine zur behandlung von schizophrenie - Google Patents

Verwendung von d-serine oder d-alanine zur behandlung von schizophrenie

Info

Publication number
ATE369848T1
ATE369848T1 AT99917453T AT99917453T ATE369848T1 AT E369848 T1 ATE369848 T1 AT E369848T1 AT 99917453 T AT99917453 T AT 99917453T AT 99917453 T AT99917453 T AT 99917453T AT E369848 T1 ATE369848 T1 AT E369848T1
Authority
AT
Austria
Prior art keywords
alanine
cycloserine
serine
alkylated
precursor
Prior art date
Application number
AT99917453T
Other languages
English (en)
Inventor
Guochuan Tsai
Joseph Coyle
Original Assignee
Gen Hospital Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gen Hospital Corp filed Critical Gen Hospital Corp
Application granted granted Critical
Publication of ATE369848T1 publication Critical patent/ATE369848T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/315—Zinc compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
AT99917453T 1998-04-14 1999-04-14 Verwendung von d-serine oder d-alanine zur behandlung von schizophrenie ATE369848T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US8164598P 1998-04-14 1998-04-14

Publications (1)

Publication Number Publication Date
ATE369848T1 true ATE369848T1 (de) 2007-09-15

Family

ID=22165468

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99917453T ATE369848T1 (de) 1998-04-14 1999-04-14 Verwendung von d-serine oder d-alanine zur behandlung von schizophrenie

Country Status (17)

Country Link
US (5) US6228875B1 (de)
EP (3) EP2338482A3 (de)
JP (1) JP2002511409A (de)
AT (1) ATE369848T1 (de)
AU (1) AU765603C (de)
CA (2) CA2328197C (de)
CY (1) CY1106898T1 (de)
DE (2) DE69936848T2 (de)
DK (1) DK1073432T3 (de)
ES (1) ES2164040T3 (de)
HK (1) HK1036583A1 (de)
HU (1) HUP0101627A3 (de)
IL (1) IL139008A0 (de)
NZ (1) NZ508160A (de)
PT (1) PT1073432E (de)
RU (1) RU2219924C2 (de)
WO (1) WO1999052519A2 (de)

Families Citing this family (146)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6355681B2 (en) * 1995-12-07 2002-03-12 Glytech, Inc. Glycine substitutes and precursors for treating a psychosis
US6512010B1 (en) * 1996-07-15 2003-01-28 Alza Corporation Formulations for the administration of fluoxetine
US8022095B2 (en) * 1996-08-16 2011-09-20 Pozen, Inc. Methods of treating headaches using 5-HT agonists in combination with long-acting NSAIDs
PT1073432E (pt) * 1998-04-14 2007-10-22 Gen Hospital Corp Utilização da d-alanina ou da d-serina para o tratamento da esquizofrenia
CA2345767A1 (en) * 1998-10-16 2000-04-27 Paul Leonce Irma De Nijs Therapy for improving cognition
US6337328B1 (en) * 1999-03-01 2002-01-08 Sepracor, Inc. Bupropion metabolites and methods of use
DE19918105C1 (de) * 1999-04-22 2000-09-21 Lohmann Therapie Syst Lts Transdermales therapeutisches System mit einem stark wirksamen Neuroleptikum
US7146209B2 (en) * 2000-05-08 2006-12-05 Brainsgate, Ltd. Stimulation for treating eye pathologies
DE60131032T2 (de) * 2000-08-25 2008-08-14 Research Corp. Technologies, Inc., Tucson Verwendung von antikonvulsiven Aminosäure zur Behandlung von Migräne
EP1420768A2 (de) * 2000-11-01 2004-05-26 Sention, Inc. Verfahren und zusammensetzungen zur regulierung des gedächtnisvermögens
US20050059743A1 (en) * 2000-11-01 2005-03-17 Sention, Inc. Methods for treating mild cognitive impairment and alzheimer's disease
US20030119884A1 (en) * 2000-11-01 2003-06-26 Epstein Mel H. Methods and compositions for regulating memory consolidation
US20030232890A1 (en) * 2000-11-01 2003-12-18 Sention, Inc. Methods for treating an impairment in memory consolidation
US20070117869A1 (en) * 2000-11-01 2007-05-24 Cognition Pharmaceuticals Llc Methods for treating coginitive impairment and improving cognition
US7619005B2 (en) * 2000-11-01 2009-11-17 Cognition Pharmaceuticals Llc Methods for treating cognitive impairment in humans with Multiple Sclerosis
US20020155170A1 (en) * 2000-11-30 2002-10-24 Walsh William John Nutrient supplements and methods for treating autism and for preventing the onset of autism
US20030185754A1 (en) * 2001-01-16 2003-10-02 Genset, S.A. Treatment of CNS disorders using D-amino acid oxidase and D-aspartate oxidase antagonists
US20030166554A1 (en) * 2001-01-16 2003-09-04 Genset, S.A. Treatment of CNS disorders using D-amino acid oxidase and D-aspartate oxidase antagonists
WO2005016319A2 (en) * 2003-08-06 2005-02-24 Emory University Acute pharmacologic augmentation of psychotherapy with enhancers of learning or conditioning
EP1383465B1 (de) * 2001-03-29 2011-08-10 Michael Davis Akute pharmakologische verstärkung einer psychotherapie mit d-cycloserine
EP1935414A3 (de) * 2001-05-02 2010-08-18 Blanchette Rockefeller Neurosciences Institute Kohlenstoffanhydrase-Aktivatoren zur Erhöhung der Auffassungsgabe und der Merkfähigkeit
EP1383497B1 (de) * 2001-05-02 2008-10-15 Blanchette Rockefeller Neurosciences Institute Kohlensäureanhydrase-aktivatoren zur verbesserung der lern- und gedächtnisleistung
US20030051728A1 (en) 2001-06-05 2003-03-20 Lloyd Peter M. Method and device for delivering a physiologically active compound
US20070122353A1 (en) 2001-05-24 2007-05-31 Hale Ron L Drug condensation aerosols and kits
US7498019B2 (en) 2001-05-24 2009-03-03 Alexza Pharmaceuticals, Inc. Delivery of compounds for the treatment of headache through an inhalation route
CA2446904A1 (en) * 2001-05-24 2003-04-03 Alexza Molecular Delivery Corporation Delivery of drug esters through an inhalation route
US7458374B2 (en) 2002-05-13 2008-12-02 Alexza Pharmaceuticals, Inc. Method and apparatus for vaporizing a compound
US7645442B2 (en) 2001-05-24 2010-01-12 Alexza Pharmaceuticals, Inc. Rapid-heating drug delivery article and method of use
US7005138B2 (en) * 2001-12-21 2006-02-28 Duramed Pharmaceuticals, Inc. Method of systematically delivering SSRIs
WO2003057151A2 (en) * 2001-12-28 2003-07-17 Teva Pharmaceutical Industries Ltd. A stable pharmaceutical formulation of paroxetine hydrochloride anhydrous and a process for preparation thereof
BE1015608A6 (fr) * 2003-07-15 2005-06-07 Messadek Jallal Traitement des arterites.
WO2003068215A1 (fr) * 2002-02-14 2003-08-21 Ajinomoto Co., Inc. Médicaments pour maladies mitochondriales
EP1487542A1 (de) * 2002-03-15 2004-12-22 H. Lundbeck A/S Verwendung von asc-1-hemmern zur behandlung von neurologischen und psychiatrischen erkrankungen
US7684859B2 (en) * 2002-04-25 2010-03-23 Brainsgate Ltd. Stimulation of the OTIC ganglion for treating medical conditions
EP1512013A2 (de) * 2002-06-10 2005-03-09 EVOTEC Neurosciences GmbH Diagnostische und therapeutische verwendung des steroidogenen akut regulatorischen proteins (star) für neurodegenerative erkrankungen
KR100446503B1 (ko) * 2002-06-19 2004-09-04 삼성전자주식회사 복합 억세스 포인트 장치 및 복합 억세스 포인트 장치를이용한 음성/데이터 패킷 처리 방법
WO2004005935A1 (ja) * 2002-07-04 2004-01-15 Mitsubishi Pharma Corporation 統合失調症の検査、診断方法
WO2004010932A2 (en) * 2002-07-30 2004-02-05 Peter Migaly Combination therapy for depression, prevention of suicide, and varous medical and psychiatric conditions
FR2843590B1 (fr) * 2002-08-14 2007-10-05 Prestwick Scient Capital Inc Derives de l'acide r(+)-2-amino-3-hydroxypropanoique a action glycinergique
DE60327634D1 (de) 2002-08-22 2009-06-25 Dainippon Sumitomo Pharma Co Mittel zur behandlung des integrationsdysfunktionssyndroms
US7160913B2 (en) 2002-09-13 2007-01-09 Thomas Jefferson University Methods and kit for treating Parkinson's disease
US20040067986A1 (en) * 2002-10-04 2004-04-08 Nathan Sassover Neuro-degenerative inhibitor, neuro-endocrine modulator, and neuro-cerebral metabolism enhancer
WO2004037289A2 (en) * 2002-10-25 2004-05-06 Pfizer Products Inc. Novel injectable depot formulations
TWI319713B (en) 2002-10-25 2010-01-21 Sustained-release tramadol formulations with 24-hour efficacy
US8487002B2 (en) * 2002-10-25 2013-07-16 Paladin Labs Inc. Controlled-release compositions
EP1585430B1 (de) * 2002-11-14 2017-01-11 Brainsgate Ltd. Chirurgische instrumente und verfahren zur stimulation
US20040105818A1 (en) 2002-11-26 2004-06-03 Alexza Molecular Delivery Corporation Diuretic aerosols and methods of making and using them
US7913688B2 (en) 2002-11-27 2011-03-29 Alexza Pharmaceuticals, Inc. Inhalation device for producing a drug aerosol
AR042806A1 (es) * 2002-12-27 2005-07-06 Otsuka Pharma Co Ltd Combinacion de derivados de carboestirilo e inhibidores de la reabsorcion de serotonina para el tratamiento de trastornos del animo
EP1575590B1 (de) 2002-12-27 2007-10-24 Otsuka Pharmaceutical Co., Ltd. Carbostyril-derivate mit selektiven serotonin-aufnahme inhibitoren, zur behandlung von gemütskrankheiten
US20070249537A1 (en) * 2003-01-23 2007-10-25 Supernus Pharmaceuticals, Inc. Absorption enhancing agents
IL154318A (en) 2003-02-06 2010-05-31 Sarah Herzog Memorial Hospital Pharmaceutical compositions for the treatment of movement disorders
DE602004003577T2 (de) * 2003-04-17 2007-09-20 Jallal Messadek Flottierende orale Formulierungen mit kontrollierter Freisetzung von Betain
WO2004100954A1 (en) * 2003-05-16 2004-11-25 Pfizer Products Inc. Treatment of psychotic and depressive disorders
ATE510174T1 (de) 2003-05-21 2011-06-15 Alexza Pharmaceuticals Inc Schlag gezündete unabhängige heizeinheit
WO2004112700A2 (en) * 2003-06-06 2004-12-29 The General Hospital Corporation Methods and compositions for modulating amyloid precursor protein translation
EP1637530A4 (de) 2003-06-23 2009-04-01 Dainippon Sumitomo Pharma Co Therapeutisches mittel für senile demenz
NZ527142A (en) * 2003-07-23 2006-03-31 Douglas Pharmaceuticals Ltd A stable suspension formulation
US7838029B1 (en) * 2003-07-31 2010-11-23 Watson Laboratories, Inc. Mirtazapine solid dosage forms
US20060128657A1 (en) * 2003-08-04 2006-06-15 Jallal Messadek Selected betaines and their uses
US20060172006A1 (en) * 2003-10-10 2006-08-03 Vincent Lenaerts Sustained-release tramadol formulations with 24-hour clinical efficacy
US20050096311A1 (en) * 2003-10-30 2005-05-05 Cns Response Compositions and methods for treatment of nervous system disorders
EP1713486A4 (de) * 2003-12-02 2009-04-29 Sheldon Leslie James Kombinationstherapie für demenz, depression und apathie
JP2007516292A (ja) * 2003-12-23 2007-06-21 ダーファーマ，インコーポレイテッド ドーパミン受容体結合化合物の共投与
US20120225916A1 (en) * 2003-12-29 2012-09-06 Mcdevitt Jason P Compositions and Methods to Improve Treatment of Medical Conditions Using D-Cycloserine
JP2007517049A (ja) 2003-12-29 2007-06-28 マクデビット、ジェイソン 再発性病状を治療するための組成物および方法
US20050171088A1 (en) * 2004-01-30 2005-08-04 Astrazeneca Ab Treatment of psychoses with dibenzothiazepine antipsychotic
EP1726952A4 (de) 2004-02-20 2008-06-18 Dainippon Sumitomo Pharma Co Verfahren zum in-vivo-screening eines therapeutikums für eine gedächtnis-/lernfehlfunktion durch schizophrenie
US8010189B2 (en) * 2004-02-20 2011-08-30 Brainsgate Ltd. SPG stimulation for treating complications of subarachnoid hemorrhage
US9233245B2 (en) 2004-02-20 2016-01-12 Brainsgate Ltd. SPG stimulation
US8055347B2 (en) 2005-08-19 2011-11-08 Brainsgate Ltd. Stimulation for treating brain events and other conditions
US7262318B2 (en) * 2004-03-10 2007-08-28 Pfizer, Inc. Substituted heteroaryl- and phenylsulfamoyl compounds
EP1735057B1 (de) * 2004-03-22 2015-02-25 Apkarian Technologies LLC Methoden und formulierungen zur behandlung von chronischem neuropathischen schmerz
TW201207390A (en) 2004-05-18 2012-02-16 Brni Neurosciences Inst Method for screening agent for antidepressant activity
US20050261278A1 (en) 2004-05-21 2005-11-24 Weiner David M Selective serotonin receptor inverse agonists as therapeutics for disease
WO2005115471A2 (en) * 2004-05-27 2005-12-08 Neurocure Ltd. Methods and compositions for treatment of nicotine dependence and dementias
US7540286B2 (en) 2004-06-03 2009-06-02 Alexza Pharmaceuticals, Inc. Multiple dose condensation aerosol devices and methods of forming condensation aerosols
EP1604656A1 (de) 2004-06-09 2005-12-14 Schwarz Pharma Ag Neue Verwendung von Peptidverbindungen zur Behandlung von amyotropher Lateralsklerose (ALS)
AU2005259961B2 (en) * 2004-06-25 2012-05-17 Board Of Regents, The University Of Texas System Methods and compositions for the treatment of attention deficit hyperactivity disorder and hyperphenylalanemia
US20050288340A1 (en) * 2004-06-29 2005-12-29 Pfizer Inc Substituted heteroaryl- and phenylsulfamoyl compounds
WO2006023703A2 (en) * 2004-08-20 2006-03-02 Cypress Bioscience, Inc. Method for treating sleep related breathing disorders
US20090299418A1 (en) * 2004-08-23 2009-12-03 Brainsgate Ltd. Concurrent bilateral spg modulation
WO2006034196A1 (en) * 2004-09-17 2006-03-30 Lifelike Biomatic Inc. Compositions for enhancing memory and methods therefor
WO2006050581A2 (en) * 2004-11-10 2006-05-18 Jallal Messadek Betaine as agent against arthropod - or mosquito -borne diseases
WO2006055854A2 (en) * 2004-11-17 2006-05-26 Cypress Bioscience, Inc. Methods for reducing the side effects associated with mirtazapine treatment
WO2006060186A2 (en) * 2004-11-30 2006-06-08 Bayer Pharmaceuticals Corporation Pyrazole derivatives for the treatment of dementia and related disorders
ES2338346T3 (es) * 2004-12-16 2010-05-06 Janssen Pharmaceutica Nv Combinacion de un inhibidor del transportador de glicina (glyt1) y un antipsicotico para el tratamiento de los sintomas de esquizofrenia asi como preparacion y uso de la misma.
JP5055493B2 (ja) * 2004-12-21 2012-10-24 メルク シャープ エンド ドーム リミテッド Ｇｌｙｔ１阻害薬としてのピペリジンおよびアゼチジン誘導体
AU2006258842B2 (en) 2005-06-13 2011-09-15 Merck Sharp & Dohme Limited Therapeutic agents
US20100048653A1 (en) * 2005-07-14 2010-02-25 The University Of British Columbia Neuroprotective modulation of nmda receptor subtype activities
PL1931346T3 (pl) * 2005-09-09 2013-01-31 Angelini Labopharm Llc Kompozycja trazodonu do podawania raz na dobę
US7834031B2 (en) 2005-09-29 2010-11-16 Merck Sharp & Dohme Corp. Radiolabeled glycine transporter inhibitors
BRPI0709146A2 (pt) * 2006-03-24 2011-06-28 Wyeth Corp métodos para tratar distúrbios cognitivos e outros distúrbios
US7884124B2 (en) 2006-06-30 2011-02-08 Sepracor Inc. Fluoro-substituted inhibitors of D-amino acid oxidase
US7531572B2 (en) * 2006-07-28 2009-05-12 Xenoport, Inc. Acyloxyalkyl carbamate prodrugs of α-amino acids, methods of synthesis and use
US20090210026A1 (en) * 2006-08-17 2009-08-20 Brainsgate Ltd. Spg stimulation for enhancing neurogenesis and brain metabolism
US20080081067A1 (en) * 2006-10-03 2008-04-03 Gupta Manishkumar Sustained release pharmaceutical compositions of venlafaxine and process for preparation thereof
WO2008055341A1 (en) * 2006-11-09 2008-05-15 Centre For Addiction And Mental Health Slc1a1 antipsychotic drug response markers
ES2594867T3 (es) 2007-03-09 2016-12-23 Alexza Pharmaceuticals, Inc. Unidad de calentamiento para usar en un dispositivo de administración de fármaco
WO2008118785A2 (en) * 2007-03-23 2008-10-02 Tikvah Therapeutics Methods for treating depression using immediate-impact treatments and d-cycloserine
WO2008124814A2 (en) * 2007-04-10 2008-10-16 Mcdevitt Jason P Sublingual formulations of d-cycloserine and methods of using same
WO2008128166A1 (en) * 2007-04-13 2008-10-23 Concert Pharmaceuticals Inc. Deuterated derivatives of 4-(6-fluoro-1, 2-benzisoxazol-3-yl) piperidine compounds
WO2008157094A1 (en) * 2007-06-13 2008-12-24 Cypress Bioscience, Inc. Improving the tolerability of mirtazapine and a second active by using them in combination
US8580776B2 (en) * 2007-07-10 2013-11-12 The Board Of Trustees Of The University Of Illinois Compositions and methods for treating neurodegenerating diseases
WO2009018368A1 (en) * 2007-07-30 2009-02-05 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Combination treatment of nmda (n-methyl-d-aspartate)-enhancer, glycine transporter inhibitor, d-amino acid oxidase inhibitor (daaoi) for neuropsychiatric disorders
US7860569B2 (en) 2007-10-18 2010-12-28 Brainsgate, Ltd. Long-term SPG stimulation therapy for prevention of vascular dementia
WO2009065193A1 (en) * 2007-11-21 2009-05-28 Jallal Messadek Treatment of aspirin resistance with betaine and/or betaine enriched molasses
IL188681A0 (en) 2008-01-09 2008-12-29 Amino Acid Solutions Inc Pharmaceutical compositions and methods utilizing a d-amino acid
EP2111858A1 (de) * 2008-04-25 2009-10-28 EPFL Ecole Polytechnique Fédérale de Lausanne Neue Behandlung für Morbus Alzheimer
GB0817379D0 (en) * 2008-09-23 2008-10-29 Merck Sharp & Dohme New use
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
US20110237537A1 (en) * 2009-05-29 2011-09-29 Lombard Jay L Methods for assessment and treatment of mood disorders via single nucleotide polymorphisms analysis
US20120041066A1 (en) * 2010-08-16 2012-02-16 Lombard Jay L Medical foods for the treatment of developmentally-based neuropsychiatric disorders via modulation of brain glycine and glutathione pathways
US8355927B2 (en) 2010-11-05 2013-01-15 Genomind, Llc Neuropsychiatric test reports
US20120148509A1 (en) * 2009-09-14 2012-06-14 Shiseido Company, Ltd. Composition for alleviating ultraviolet irradiation-induced damage
TWI544923B (zh) * 2009-12-29 2016-08-11 何應瑞 用於治療神經退化性疾病之醫藥組合物
WO2011104298A1 (en) * 2010-02-24 2011-09-01 Universität Zürich Prevention and treatment of diseases caused by elevated levels of deoxy-sphingolipids
US8258139B2 (en) 2010-11-08 2012-09-04 Dainippon Sumitomo Pharma Co., Ltd. Method of treatment for mental disorders
JP2014502958A (ja) * 2010-11-12 2014-02-06 プロメンテイス・フアーマシユーテイカルズ・インコーポレイテツド Ｓ−ｔ−ブチル保護システインジペプチド類似体および関連化合物
WO2012104852A1 (en) * 2011-01-31 2012-08-09 Serotech, Llc Dosage regimen, medication dispensing package and uses thereof for the treatment of major depressive disorder
US10583138B2 (en) 2012-07-12 2020-03-10 Glytech, Llc Composition and method for treatment of depression and psychosis in humans
US9737531B2 (en) * 2012-07-12 2017-08-22 Glytech, Llc Composition and method for treatment of depression and psychosis in humans
CA2855854C (en) 2011-11-21 2020-03-31 The Institute For Ethnomedicine L-serine compositions, methods and uses for treating neurodegenerative diseases and disorders
US20130296430A1 (en) * 2012-05-03 2013-11-07 Antonio Hardan Compositions and methods for treating autism and autism spectrum disorder
KR101499299B1 (ko) * 2012-08-03 2015-03-09 연세대학교 산학협력단 Ｓｈａｎｋ2 유전자가 결실된 자폐증 모델 형질전환마우스 및 그 용도
EP2882304A1 (de) * 2012-08-07 2015-06-17 Buck Institute For Research On Aging Mehrkomponentige formulierung zur verbesserung der neurologischen funktion
US9265458B2 (en) 2012-12-04 2016-02-23 Sync-Think, Inc. Application of smooth pursuit cognitive testing paradigms to clinical drug development
US9380976B2 (en) 2013-03-11 2016-07-05 Sync-Think, Inc. Optical neuroinformatics
AT514349B1 (de) * 2013-06-12 2018-05-15 Red Bull Gmbh Alpha-alkylierte Aminosäuren (AAAAs)
US20160206583A1 (en) * 2013-08-27 2016-07-21 The Johns Hopkins University Amino acid treatment of seizures
US9675796B2 (en) 2013-11-10 2017-06-13 Brainsgate Ltd. Implant and delivery system for neural stimulator
US9877951B2 (en) 2015-02-12 2018-01-30 College Of William And Mary Method for treating dementia
CN107636466B (zh) 2015-02-18 2020-07-21 阿斯顿大学 先兆子痫的诊断性测定和治疗
EP3291800A4 (de) 2015-05-04 2018-09-26 Confluence Pharmaceuticals, LLC Rieselformulierungen von acamprosat
US10271907B2 (en) 2015-05-13 2019-04-30 Brainsgate Ltd. Implant and delivery system for neural stimulator
KR20180034442A (ko) * 2015-08-04 2018-04-04 컨플루언스 파마슈티컬스, 엘엘씨 아캄프로세이트와 d-사이클로세린을 사용한 병용 치료
US20170143681A1 (en) 2015-11-02 2017-05-25 Apkarian Technologies Llc Methods and compositions for treating pain
CN105476976B (zh) * 2015-12-22 2018-09-25 广州瑞尔医药科技有限公司 药物组合物及其制备方法和应用
WO2017205666A1 (en) * 2016-05-25 2017-11-30 National Health Research Institutes Method and composition for decreasing the psychotomimetic side effect and addictive disorder of ketamine
US9877942B1 (en) * 2017-02-13 2018-01-30 Syneurx International (Taiwan) Corp. Co-crystals of substituted glycine and uses thereof
KR102608479B1 (ko) * 2017-05-25 2023-12-01 글리테크 엘엘씨. Nmdar 길항제-반응성 신경정신 질환을 위한 병용 요법
US10226442B2 (en) * 2017-07-10 2019-03-12 Syneurx International (Taiwan) Corp. Lithium salts of N-substituted glycine compounds and uses thereof
CA3082834A1 (en) 2017-11-22 2019-05-31 Concert Pharmaceuticals, Inc. Deuterated analogs of d-serine and uses thereof
KR101952443B1 (ko) * 2018-08-23 2019-02-26 주식회사 아스트로젠 신규한 마그네슘­세리네이트 화합물 및 이의 용도
JP2023549174A (ja) * 2020-11-04 2023-11-22 グリアセルテック・インコーポレイテッド クロルプロマジンを含む神経炎症性疾患の予防または治療用組成物
WO2023171106A1 (ja) * 2022-03-08 2023-09-14 ソシウム株式会社 Ｔｄｐ－４３の凝集の抑制剤、ｔｄｐ－４３が過剰発現している細胞の細胞死の抑制剤、及びｔｄｐ－４３の凝集を伴う疾患の治療又は予防剤

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3873722A (en) 1974-05-31 1975-03-25 Nelson Res & Dev Method for treating schizophrenia
JPS5520747A (en) * 1978-08-01 1980-02-14 Sumitomo Chem Co Ltd Antidepressant
US5051448A (en) 1984-07-24 1991-09-24 The Mclean Hospital Corporation GABA esters and GABA analog esters
US4904681A (en) * 1987-12-01 1990-02-27 G. D. Searle & Co. D-cycloserine and its prodrugs as cognitive enhancers
US5468763A (en) 1987-12-01 1995-11-21 G. D. Searle & Co. Use of a glycine B partial agonist for memory and learning enhancement or treatment of a cognitive disorder
US5015740A (en) 1988-08-05 1991-05-14 Janssen Pharmaceutica N.V. Antipsychotic 3-piperazinylbenzazole derivatives
US5187171A (en) * 1989-01-09 1993-02-16 G. D. Searle & Co. Use of a glycine b partial agonist as an antipsychotic
US5061721A (en) * 1989-03-15 1991-10-29 G. D. Searle & Co. Composition containing d-cycloserine and d-alanine for memory and learning enhancement or treatment of a cognitive or psychotic disorder
US6294520B1 (en) 1989-03-27 2001-09-25 Albert T. Naito Material for passage through the blood-brain barrier
JPH03236315A (ja) * 1989-12-05 1991-10-22 Nippon Oil & Fats Co Ltd 抗精神病薬
US5260324A (en) 1990-02-06 1993-11-09 G. D. Searle & Company Composition containing D-cycloserine and D-alanine for memory and learning enhancement or treatment of a cognitive or psychotic disorder
US5086072A (en) * 1990-06-18 1992-02-04 The United States Of America As Represented By The Department Of Health And Human Services Treatment of mood disorders with functional antagonists of the glycine/nmda receptor complex
US5168103A (en) 1991-01-22 1992-12-01 American Home Products Corporation [[2-(amino-3,4-dioxo-1-cyclobuten-1-yl) amino]alkyl]-acid derivatives
DE4117629A1 (de) 1991-05-29 1992-12-03 Max Planck Gesellschaft Phospatidylserine
ATE161530T1 (de) 1992-09-04 1998-01-15 Takeda Chemical Industries Ltd Kondensierte heterozyklische verbindungen, deren herstellung und verwendung
GB9300051D0 (en) 1993-01-04 1993-03-03 Merck Sharp & Dohme Therapeutic agents
CA2160459A1 (en) * 1993-04-27 1994-11-10 Ichio Noda Serine derivative
JPH0826986A (ja) * 1994-07-21 1996-01-30 Yamanouchi Pharmaceut Co Ltd 抗フェンサイクリジン薬
RU2096044C1 (ru) 1995-07-19 1997-11-20 Малое предприятие "Ветта" Ветеринарный имплантируемый препарат для регулирования биологического ритма животных
US6361957B1 (en) 1999-08-03 2002-03-26 Glytech, Inc. Assay for D-serine transport antagonist and use for treating psychosis
US6355681B2 (en) 1995-12-07 2002-03-12 Glytech, Inc. Glycine substitutes and precursors for treating a psychosis
WO1997020552A1 (en) 1995-12-07 1997-06-12 Albert Einstein College Of Medicine Of Yeshiva University Treatment of negative and cognitive symptoms of schizophrenia with glycine and its precursors
SK285854B6 (sk) * 1996-05-31 2007-09-06 Allelix Neuroscience Inc. Substituovaný amín, spôsoby jeho prípravy a použitie, farmaceutický prostriedok a jeho použitie
PT1073432E (pt) 1998-04-14 2007-10-22 Gen Hospital Corp Utilização da d-alanina ou da d-serina para o tratamento da esquizofrenia
WO1999061438A1 (en) 1998-05-23 1999-12-02 Byk Gulden Lomberg Chemische Fabrik Gmbh Quinoline-aminomethyl-pyridyl derivatives with anti-helicobacter activity
US6551993B1 (en) 1999-08-16 2003-04-22 Thomas Jefferson University Partial agonists at the glycine modulatory site of the NMDA receptor for treating cognitive dysfunction

Also Published As

Publication number Publication date
EP2338482A3 (de) 2011-12-21
EP1073432A2 (de) 2001-02-07
CA2328197A1 (en) 1999-10-21
EP1844769A2 (de) 2007-10-17
US6667297B2 (en) 2003-12-23
US20050250851A1 (en) 2005-11-10
CA2601132C (en) 2011-11-08
NZ508160A (en) 2004-01-30
DK1073432T3 (da) 2007-12-17
EP1073432B1 (de) 2007-08-15
HK1036583A1 (en) 2002-01-11
IL139008A0 (en) 2001-11-25
RU2219924C2 (ru) 2003-12-27
ES2164040T3 (es) 2008-02-01
US6420351B1 (en) 2002-07-16
EP2338482A2 (de) 2011-06-29
US20040092530A1 (en) 2004-05-13
AU765603C (en) 2004-08-05
US6974821B2 (en) 2005-12-13
US7704978B2 (en) 2010-04-27
JP2002511409A (ja) 2002-04-16
PT1073432E (pt) 2007-10-22
US20020193429A1 (en) 2002-12-19
AU3557199A (en) 1999-11-01
DE69936848T2 (de) 2008-05-15
AU765603B2 (en) 2003-09-25
HUP0101627A3 (en) 2003-02-28
WO1999052519A3 (en) 1999-12-02
WO1999052519A2 (en) 1999-10-21
CA2328197C (en) 2007-11-20
DE1073432T1 (de) 2002-02-07
ES2164040T1 (es) 2002-02-16
US6228875B1 (en) 2001-05-08
US20020035145A1 (en) 2002-03-21
DE69936848D1 (de) 2007-09-27
HUP0101627A2 (hu) 2001-10-28
EP1844769A3 (de) 2010-02-10
CA2601132A1 (en) 1999-10-21
CY1106898T1 (el) 2012-09-26

Similar Documents

Publication Publication Date Title
ATE369848T1 (de) Verwendung von d-serine oder d-alanine zur behandlung von schizophrenie
CY2018020I2 (el) Θεραπεια της νοσου ρομρε
CY1110448T1 (el) Ενωσεις ριλουζολης και λεβαντοπας για τη θεραπεια της ασθενειας του παρκινσον
BR9808938A (pt) Composto, composição farmacêutica, uso de um composto, processos para o tratamento de um distúrbio ou doença de um corpo de animal vivo e para a preparação de um composto, e, uso de bloqueadores de canal de cloreto
FI971974A (fi) Tienopyridiini- tai tienopyrimidiinijohdannaiset ja niiden käyttö
NZ516599A (en) 2-arylimino-2,3-dihydrothiazoles, and their use thereof as somatostatin receptor ligands
IL128877A0 (en) Highly selective butyrylcholinesterase inhibitors for the treatment and diagnosis of alzheimer's disease and dementias
DE60042496D1 (de) Verwendung von retinoid rezeptor antagonisten für die behandlung von knochen und knorpel pathologien
DE69229442D1 (de) Substituierte dibenzooxazepin-verbindungen, pharmazeutische zusammensetzungen und verfahren zur verwendung
BR9711225A (pt) Composi-{es de propentofilina transd-rmica para o tratamento do mal de alzheimer
ES2157565T3 (es) N-azacicloalquilalquildibenzotiofenocarboxamidas: ligandos especificos de un subtipo de receptor de la dopamina.
ATE303362T1 (de) Chalcon-derivate mit antiproliferativer aktivität
ATE446748T1 (de) Verwendung von r-carprofen zur vorbeugung der alzheimerschen krankheit
PL350568A1 (en) N-(2-phenyl-4-aminobutyl)-1-naphtamides as antagonists of neurokinin 1 receptors
ES2177024T3 (es) Empleo de la fanquinoma para el tratamiento de la enfermedaad de alzheimer.
IS5951A (is) 5HT1 mótlyf fyrir meðferð gegn þunglyndi
BR9812085A (pt) "método para a sìntese de derivados de quinolina"
BR9908217A (pt) Composição desodorante, e, processo para inibição de odor corporal
FI971127A0 (fi) 2,4-diaminopyrimidiini-3-oksidin tai jonkin sen suolan käyttö kollageenin kypsymis- ja rakentumishäiriöiden hoitamiseen
BR0015781A (pt) Composição farmacêutica para tratamento de doenças associadas à diminuição de massa óssea
DK0804186T3 (da) Indolditerpenalkaloidforbindelser
ID20165A (id) Penggunaan asam 2-(3,4-dimetoksisinamoil)aminobenzoat untuk pembuatan obat untuk pengobatan atau pencegahan restenosis
BR9604843A (pt) Peptìdeo e derivado do mesmo, e, droga e composição para tratar osteopatia
BR9815004A (pt) Composições estabilizadas de amaciamento de tecidos.
SE9501773D0 (sv) New use

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1073432

Country of ref document: EP